Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Half-life extension using serum albumin-binding DARPin® domains

14 Apr 2017

Abstract excerpt

A long systemic half-life is key for therapeutic proteins. To that end we have generated serum albumin-binding designed ankyrin repeat domains. These domains bind serum albumin of different species with nanomolar affinities, and have significantly improved pharmacokinetic properties both in mouse and cynomolgus monkey compared to non-serum albumin-binding DARPin® domains. In addition, they exhibit high thermal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biosimilars and Bioanalytical Methods
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29088432
DOI: 10.1093/protein/gzx022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Half-life extension using serum albumin-binding DARPin® domainsPMID 29088432Read ↗

A resource of high-quality and versatile nanobodies for drug deliverySemantic proximity Read ↗

Anti-serum albumin domain antibodies for extending the half-lives of short lived drugsSemantic proximity Read ↗

Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and TherapySemantic proximity Read ↗

Quantitative Prediction of Human Pharmacokinetics for Fc-Engineered Therapeutic Monoclonal Antibodies With Increased FcRn Binding Mutations After Subcutaneous Injection.Semantic proximity Read ↗

Serum albumin‐binding V H Hs with variable pH sensitivities enable tailored half‐life extension of biologicsSemantic proximity Read ↗

Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations.Semantic proximity Read ↗

Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokineticsSemantic proximity Read ↗

A Decade of Clinical Experience with DARPins in Oncology and Virology: A Systematic ReviewSemantic proximity Read ↗

A Physiologically-Based Pharmacokinetic Model for the Prediction of "Half-Life Extension" and "Catch and Release" Monoclonal Antibody Pharmacokinetics.Semantic proximity Read ↗

Crystal structure of human serum albumin in complex with megabody reveals unique human and murine cross‐reactive binding siteSemantic proximity Read ↗

Engineered human IgG antibodies with longer serum half-lives in primates.Semantic proximity Read ↗

Engineered human FcγRIIa fusion: A novel strategy to extend serum half-life of therapeutic proteins.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.